

Guide to Improve Outcomes for Retinal Diseases

Payer Opportunity

Roadmap to Preventing Blindness: Managed Care Findings from AMCP Market Insights: Chief Medical and Pharmacy Officers Summit

includes payer opportunities (\$) to support more optimal care delivery and outcomes.

of patients with diabetes in the United States (US)

disease management and improve treatment for populations of patients with diabetes at high risk for blindness.


Retinal diseases in patients with diabetes pose significant challenges for health care systems. With a high treatment

barriers that impact timely treatment with anti-VEGF therapies. This roadmap outlines essential points to better retinal

burden and advances in durable therapies, managed care organizations can optimize patient care by addressing coverage

Early and regular screening for diabetic retinopathy (DR) and diabetic macular edema (DME) is critical to prevent vision loss in diabetic patients.

Healthcare



Screening

There is an increasing prevalence of DR, estimated in 2021 to be 26.43%

receive annual screening exams.^{1,2}



cost-effective intervention.4

Role of Ophthalmologists

Managing diabetes

related complications.

health care professional.

and blindness risk.

No insurance

Minority race/ethnicity:

of patients with diabetes in the US are diagnosed with DR.³

Screening for retinopathy in patients with diabetes is a

Ophthalmologists play a critical role in preventing blindness for patients with diabetes.

Monitoring for retinal

disease progression.

Enhance Screening:





detection and early intervention rates



percentage of members 18–75 years of age with diabetes (type 1 or type 2) who had a retinal eye exam.⁵



are well-represented in provider networks to support early intervention

and timely referrals for retinal disease. Consider incentivizing ophthalmologist visits within diabetes care plans to encourage routine



support, education on diabetes and eye health, and financial support for patients.

that address SDOH.



outreach and connect patients to resources

Support SDM Initiatives:

Encourage SDM to improve patient

adherence and health outcomes.

Key risk factors for vision impairment and blindness include: 6 Odds ratio (OR) 95%CI

Patients with a retinal disease may visit their

ophthalmologist more frequently than any other

Social Determinants of Health (SDOH)

11.85 Older age (≥85 years) 10.33 13.59 Individuals with: 3.85 3.57 4.15 Medicaid 1.77


1.37 2.27

1.73

Barriers can influence screening rates and treatment adherence while

key risk factors such as age and race are correlated to vision impairment

1.66 1.53 • 1.82 Medicare



Baseline visual **Ophthalmic** Anatomic history characteristics accuity









Payer-Provider Partnerships:


Develop stronger payer-provider

partnerships to ensure effective

treatment pathways.

Ophthalmologists generally consider all anti-VEGF

agents to be safe and effective treatments for retinal



~12 Hour Commitment • 1 hour of travel 1.5 hours waiting & treatment 9 hours recovery



1,423 out of 2,225 of these approvals

were reauthorizations for previously

are approved.¹¹

used medication.¹¹

Longer-acting anti-VEGF therapies may reduce

particularly for older or underserved patients who

face challenges attending frequent appointments.

treatment burden and improve adherence,

Technology

Technological advances like

and expanded access to

retinal care, particularly for

underserved populations.

telemedicine and AI screening

tools enable earlier intervention

Support Use of

Telemedicine &

Support telemedicine

access to care in rural

and underserved areas.

Partner with providers

to implement these

potentially reducing

costs associated with

disease progression.

delayed treatment and

technologies,

screening tools to extend

solutions and Al

AI Tools:

64%



Part B drugs.¹²

Engage in value-based contracts with drug manufacturers or providers. Consider adjustments based on real-world effectiveness, which can help manage costs while

Support Value

Based Agreements:

ensuring high-quality care.

Looking forward, anti-VEGF

health care costs if they are

priced less than reference

products and (repackaged)

biosimilars may reduce

bevacizumab may continue to be less expensive than biosimilars.



Consider Treatment Advances: Remaining adherent to vision-preserving

treatment is often a

challenge for patients.

A more comprehensive

approach to managing

retinal health for patients

Simplify Utilization Management: Reduce prior authorization

health, and treatment adherence is essential for preventing disease progression and improving patient engagement. Provide provider education on the costs of treatments for retinal diseases.

Invest in Patient

Develop or support

inform patients about

and the importance of

regular screening and

treatment adherence.

Education Programs:

educational resources that

diabetes-related eye health

This can include educational

materials in provider offices,

complications and preventive

decision-making, enhance

value-based care, and ensure

community programs. **Promote Diabetes & Retinal Awareness:** Collaborate with community organizations and health care providers to increase awareness of diabetic eye

online modules, or

alignment with patients' clinical and financial needs.

Summary

References

Effective retinal disease management in patients with diabetes requires a multifaceted approach that balances clinical efficacy, cost-effectiveness, and timely access to treatment. Ophthalmologists play a central role in preventing vision loss through early screening and timely access to recommended treatments. Key strategies from executive health care leaders focus on fostering payer-provider collaboration, integrating diabetes management education within retinal care settings, and leveraging durable, long-acting treatment options to improve outcomes and address treatment burdens.

2. Increase the proportion of adults with diabetes who have a yearly eye exam — D-04 - Healthy People 2030. Accessed October 24, 2024. https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/diabetes/increase-proportion-adults-diabetes-who-have-yearly-eye-exam-d-04 3. Lundeen EA, Burke-Conte Z, Rein DB, et al. Prevalence of Diabetic Retinopathy in the US in 2021. JAMA Ophthalmol. 2023;141(8):747–754. 4. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med. 2010 Mar;27(3):249-56

9. Mukamal R. Comparison of Anti-VEGF Treatments for Wet AMD. Accessed December 9, 2024.

https://www.aao.org/eye-health/diseases/avastin-eylea-lucentis-difference May. 23, 2024.

For more information, read the full JMCP supplement:

Care & Specialty Pharmacy. 2025 31:4-a Suppl, S1-S11.

Settings. JAMA Ophthalmol. 2019;137(4):440-444.

https://www.jmcp.org/doi/10.18553/jmcp.2025.31.4-a.s1

Population Disparities in Ophthalmic Care: Blindness and Visual Impairment in the IRIS® Registry (Intelligent Research in Sight). Ophthalmology. 2023 Nov;130(11):1121-1137. 7. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020 Jan;127(1):P66-P145. 8. Turbert D. Anti-VEGF Treatments. Accessed December 9, 2024. https://www.aao.org/eye-health/drugs/anti-vegf-treatments. Jul. 26, 2023.

6. Brant A, Kolomeyer N, Goldberg JL, Haller J, Lee CS, Lee AY, Lorch AC, Lum F, Miller JW, Parke DW 2nd, Hyman L, Pershing S. United States


1. Gibson DM. Estimates of the Percentage of US Adults With Diabetes Who Could Be Screened for Diabetic Retinopathy in Primary Care

11. Dang S, Parke DW, Sodhi GS, et al. Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA *Ophthalmol.* 2024;142(8):716–721. 12. Cubanski J, Sroczynski N, Neuman T. Medicare Part B Drugs: Cost Implications for Beneficiaries in Traditional Medicare and Medicare

Advantage. KFF. Published March 15, 2022. Accessed October 24, 2024. https://www.kff.org/medicare/issue-brief/medicare-part-b-drugs-cost-implications-for-beneficiaries-in-traditional-medicare-and-medicare-advantage/

Learn more at https://www.amcp.org/marketinsights or https://managedcareeye.com/

(EED) assesses the

























Lockhart CM, Barakat MR, Dunn JD, Richardson T, Bratcher T, Greene E, Kobernick M, Schneider D, Wigginton J. Journal of Managed

5. National Commitee for Quality Assurance. HEDIS Measures and Technical Resources. Eye Exam for Patients With Diabetes. https://www.ncqa.org/hedis/measures/eye-exam-for-patients-with-diabetes/. Accessed February 2025.

10. Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study. *Am J Ophthalmol*. 2015 Oct;160(4):725-31.e1.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals Inc. Provided by: Impact Education LLC